PeptideDB

ELOVL1-IN-3 2761063-99-2

ELOVL1-IN-3 2761063-99-2

CAS No.: 2761063-99-2

ELOVL1-IN-3 (Compound 22) is a potent and orally bioactive inhibitor of the enzyme elongation of very long chain fatty a
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

ELOVL1-IN-3 (Compound 22) is a potent and orally bioactive inhibitor of the enzyme elongation of very long chain fatty acid 1 (ELOVL1). ELOVL1-IN-3 is a useful tool for studying adrenoleukodystrophy (ALD).

Physicochemical Properties


Molecular Formula C21H23N5O2
Molecular Weight 377.44
Exact Mass 377.185
CAS # 2761063-99-2
Appearance Colorless to light yellow oil
LogP 2.6
SMILES

N1(C2C=C(O[C@@H]3C[C@H](N4C=CC=N4)C3)N=CN=2)CCO[C@@H](C2=CC=CC=C2)C1

InChi Key JXGFJBHPOCYADP-CTWPCTMYSA-N
InChi Code

InChI=1S/C21H23N5O2/c1-2-5-16(6-3-1)19-14-25(9-10-27-19)20-13-21(23-15-22-20)28-18-11-17(12-18)26-8-4-7-24-26/h1-8,13,15,17-19H,9-12,14H2/t17?,18?,19-/m1/s1
Chemical Name

(2S)-2-phenyl-4-[6-(3-pyrazol-1-ylcyclobutyl)oxypyrimidin-4-yl]morpholine
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets ELOVL1[1]
References [1]. Boyd MJ, et al. Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1. J Med Chem. 2021;64(24):17777-17794.

Solubility Data


Solubility (In Vitro) DMSO :~100 mg/mL (~264.94 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.5 mg/mL (6.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (6.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 2.5 mg/mL (6.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.6494 mL 13.2471 mL 26.4943 mL
5 mM 0.5299 mL 2.6494 mL 5.2989 mL
10 mM 0.2649 mL 1.3247 mL 2.6494 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.